ECSP10010231A - Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. - Google Patents

Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.

Info

Publication number
ECSP10010231A
ECSP10010231A EC2010010231A ECSP10010231A ECSP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC 2010010231 A EC2010010231 A EC 2010010231A EC SP10010231 A ECSP10010231 A EC SP10010231A EC SP10010231 A ECSP10010231 A EC SP10010231A
Authority
EC
Ecuador
Prior art keywords
beta
selective inhibitors
derivatives
azaindol
dehydrogenase type
Prior art date
Application number
EC2010010231A
Other languages
English (en)
Inventor
Denis Carniato
Melanie Schultz
Didier Roche
Sophie Hallakou-Bozec
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010231A publication Critical patent/ECSP10010231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invención se refiere a derivados 7-azaindol de fórmula I, como inhibidores selectivos de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 (11?-HSD-1) y el uso de dichos compuestos para el tratamiento y prevención del síndrome metabólico, diabetes, resistencia a la insulina, obesidad, trastornos lipídicos, glaucoma, osteoporosis, trastornos cognitivos, ansiedad, depresión, trastornos inmunitarios, hipertensión y otras enfermedades y afecciones.
EC2010010231A 2007-11-05 2010-06-03 Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1. ECSP10010231A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291325 2007-11-05

Publications (1)

Publication Number Publication Date
ECSP10010231A true ECSP10010231A (es) 2010-07-30

Family

ID=40445347

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010231A ECSP10010231A (es) 2007-11-05 2010-06-03 Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.

Country Status (23)

Country Link
US (1) US8470849B2 (es)
EP (1) EP2247589B1 (es)
JP (1) JP5529743B2 (es)
KR (1) KR101624596B1 (es)
CN (1) CN101848910B (es)
AU (1) AU2008324525B2 (es)
BR (1) BRPI0819219B1 (es)
CA (1) CA2704803C (es)
CO (1) CO6270308A2 (es)
CY (1) CY1113645T1 (es)
DK (1) DK2247589T3 (es)
EA (1) EA019707B1 (es)
EC (1) ECSP10010231A (es)
ES (1) ES2400105T3 (es)
HR (1) HRP20130097T1 (es)
IL (1) IL205508A (es)
MX (1) MX2010004815A (es)
PL (1) PL2247589T3 (es)
PT (1) PT2247589E (es)
SI (1) SI2247589T1 (es)
UA (1) UA102379C2 (es)
WO (1) WO2009059666A1 (es)
ZA (1) ZA201004023B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2543692T3 (es) * 2010-04-29 2015-08-21 The University Of Edinburgh (8-aza-biciclo[3.2.1biciclo[oct-8-il)-[5-(1H-pirazol-4-il)-tiofeno-3-il]-metanonas 3,3-disustituidas como inhibidores de 11beta-HSD1
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
PH12019502776A1 (en) 2017-06-30 2020-10-26 Univ California Compositions and methods for modulating hair growth
CN115052876A (zh) * 2019-12-20 2022-09-13 加利福尼亚大学董事会 促进毛发生长的化合物的合成
US20240327400A1 (en) * 2020-06-30 2024-10-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
US12559490B2 (en) 2020-06-30 2026-02-24 The Regents Of The University Of California Compositions and methods for modulating hair growth
CN116546984A (zh) * 2020-09-28 2023-08-04 耶鲁大学 5-ht2a受体的选择性激动剂及其使用方法
CN112390815B (zh) * 2020-11-03 2022-07-26 浙江医药股份有限公司新昌制药厂 一种Lewis酸脱N-苄基制备d-生物素的制备方法
CN112409353A (zh) * 2020-11-27 2021-02-26 苏州艾缇克药物化学有限公司 一种7-氮杂吲哚衍生物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116323A (pt) * 2000-12-22 2003-10-14 Wyeth Corp Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10337184A1 (de) * 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
ES2634841T3 (es) * 2003-10-14 2017-09-29 Pfizer Products Inc. Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina
WO2007050381A2 (en) * 2005-10-24 2007-05-03 Janssen Pharmaceutica, N.V. 3-piperidin-4-yl-indole orl-1 receptor modulators
US7638062B2 (en) 2006-07-10 2009-12-29 Cameron International Corporation Ultra compact cyclonic flotation system

Also Published As

Publication number Publication date
EA201000751A1 (ru) 2010-12-30
WO2009059666A1 (en) 2009-05-14
JP2011502135A (ja) 2011-01-20
ZA201004023B (en) 2011-03-30
CA2704803A1 (en) 2009-05-14
EP2247589A1 (en) 2010-11-10
PL2247589T3 (pl) 2013-03-29
CY1113645T1 (el) 2016-06-22
KR20100094500A (ko) 2010-08-26
CO6270308A2 (es) 2011-04-20
CN101848910B (zh) 2013-12-04
JP5529743B2 (ja) 2014-06-25
IL205508A (en) 2013-06-27
EA019707B1 (ru) 2014-05-30
AU2008324525A1 (en) 2009-05-14
EP2247589B1 (en) 2012-11-21
AU2008324525B2 (en) 2014-09-18
US8470849B2 (en) 2013-06-25
HRP20130097T1 (hr) 2013-02-28
KR101624596B1 (ko) 2016-05-26
IL205508A0 (en) 2010-12-30
BRPI0819219A2 (pt) 2020-08-04
DK2247589T3 (da) 2013-01-21
SI2247589T1 (sl) 2013-03-29
CA2704803C (en) 2017-04-11
PT2247589E (pt) 2013-02-20
MX2010004815A (es) 2010-05-27
CN101848910A (zh) 2010-09-29
ES2400105T3 (es) 2013-04-05
UA102379C2 (ru) 2013-07-10
BRPI0819219B1 (pt) 2021-09-21
US20100267761A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
CO6331305A2 (es) Nuevos derivados de nip tiazol como inhibidores de la 11-beta- hidroxiesteriode deshidrogenasa-1
MX2010004815A (es) Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
BRPI0619839B8 (pt) derivados de 2-adamantiluréia, seu método de preparação e seus usos, composição farmacêutica, e kit
ECSP088833A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
IL184328A0 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase
ECSP13012900A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
MX347145B (es) Derivados de adamantilo-acetamida como inhibidores de la enzima tipo i de 11-beta-hidroxiesteroide deshidrogenasa.
NI201000013A (es) Sulfonamidas como moduladores del trpm8
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
BRPI0606228A2 (pt) inibidores de enzima 11-beta-hidroxiesteróide desidrogenase tipo 1
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
CR11183A (es) Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1
ATE556050T1 (de) Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
UY32778A (es) Terapia de combinación para el tratamiento de la diabetes
WO2016172631A8 (en) Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
MX2011011082A (es) Derivados de amida y amidina novedosos y usos de los mismos.
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CO6321281A2 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.